Security Snapshot

Vaxcyte, Inc. - Common Stock, $0.001 par value per share (PCVX) Institutional Ownership

CUSIP: 92243G108

13F Institutional Holders and Ownership History from Q2 2020 to Q1 2026

Latest Period

Q1 2026

Institutions Reporting

335

Shares (Excl. Options)

162,525,689

Price

$58.11

Save this security page for your next review

Keep this CUSIP in your watchlists so you can revisit quarter changes from one place. If you create an account from here, we will bring you back after verification.

Latest holder snapshot 5 signals
Portfolio coverage rank
0.01%
Share change
+12,752,357
Value change
+$770,402,392
Number of holders
335
Issuer context Names, identifiers, and filing context for this profile. 3 identity fields
Shares outstanding
145,782,011
SEC-reported price per share
$53.99
Insider filing price
$53.99
13F Shares, Excluding Options vs Price
13F Value, Excluding Options
Total Investors

Key facts

  • PCVX - Vaxcyte, Inc. - Common Stock, $0.001 par value per share is tracked under CUSIP 92243G108.
  • 335 institutions reported positions in Q1 2026.
  • 6 significant owners is listed from Schedule 13D/13G reporting.

Change

  • Holder count moved from 293 to 335 between Q4 2025 and Q1 2026.
  • SEC-reported value moved from $6,807,567,397 to $9,435,685,334.

Research use

  • You can quickly see who holds this security, then open quarter and manager detail pages for full evidence.
  • 13F and Schedule 13D/13G sections are kept together so you can cross-check institutional and beneficial ownership context.

Evidence

Source: SEC Form 13F

Latest holder context comes from 335 institutions filings for Q1 2026.

Open SEC evidence

Security key

92243G108

Latest holder period

Q1 2026

13F holders

335

13D/G owners

6

CIK / CUSIP context first

13D/G owners

Significant owners

Large-stake holder rows connected to Schedule 13D/G evidence.

Rows
6
Security
PCVX
Filer Ownership Change % Holdings Value Net Change Nb Shares Change % Reporting Name Report Period
JANUS HENDERSON GROUP PLC 12% +14% $1,023,560,281 +$214,375,746 16,575,875 +26% JANUS HENDERSON GROUP PLC 31 Mar 2026
FMR LLC 11% +13% $1,015,853,037 +$204,901,073 16,451,061 +25% FMR LLC 31 Mar 2026
RA CAPITAL MANAGEMENT, L.P. 8.9% -10% $801,181,488 +$624,169 12,974,599 +0.08% RA Capital Management, L.P. 31 Mar 2026
T. Rowe Price Investment Management, Inc. 8.6% +37% $520,196,135 +$137,268,465 11,296,333 +36% T. Rowe Price Investment Management, Inc. 31 Dec 2025
BlackRock, Inc. 7.6% $323,263,490 9,825,638 BlackRock, Inc. 31 Mar 2025
VANGUARD CAPITAL MANAGEMENT LLC 5% $421,416,800 7,252,053 Vanguard Capital Management 31 Mar 2026

As of 31 Mar 2026, 335 institutional investors reported holding 162,525,689 shares of Vaxcyte, Inc. - Common Stock, $0.001 par value per share (PCVX). This represents 111% of the company’s total 145,782,011 outstanding shares.

13F concentration

Top 25 institutional shareholders

Largest 13F positions for this security by reported shares and value.

Top holder share
87%
Institution Ownership % Shares Held Share Change % Portfolio % Holdings Value
JANUS HENDERSON GROUP PLC 11% 16,575,875 +24% 0.46% $960,231,221
FMR LLC 11% 16,492,861 +19% 0.05% $958,400,171
T. Rowe Price Investment Management, Inc. 8.3% 12,126,017 +7.3% 0.49% $704,643,000
RA CAPITAL MANAGEMENT, L.P. 7.9% 11,474,599 +7% 7.1% $666,788,948
BlackRock, Inc. 7.5% 10,971,816 +7.1% 0.01% $637,572,225
VANGUARD PORTFOLIO MANAGEMENT LLC 4.3% 6,279,545 0% 0.02% $364,904,360
VANGUARD CAPITAL MANAGEMENT LLC 4.3% 6,266,701 0% 0.01% $364,157,995
WELLINGTON MANAGEMENT GROUP LLP 3.9% 5,614,597 -5.9% 0.06% $326,264,231
Paradigm Biocapital Advisors LP 3.3% 4,793,020 +18% 5.7% $278,522,392
STATE STREET CORP 3% 4,440,519 -11% 0.01% $258,038,559
Deep Track Capital, LP 2.9% 4,300,000 +7.5% 5.2% $249,873,000
WESTFIELD CAPITAL MANAGEMENT CO LP 2.5% 3,646,138 +3% 0.89% $211,877,079
GEODE CAPITAL MANAGEMENT, LLC 2.2% 3,201,283 +12% 0.01% $186,061,327
Kynam Capital Management, LP 2% 2,922,335 0% 11% $169,816,887
D. E. Shaw & Co., Inc. 2% 2,865,318 -21% 0.13% $166,503,629
Caligan Partners LP 1.4% 2,060,719 +21% 8.5% $119,748,381
JENNISON ASSOCIATES LLC 1.2% 1,698,011 +151% 0.07% $98,671,420
Polar Capital Holdings Plc 0.98% 1,425,788 -15% 0.36% $82,852,541
CHARLES SCHWAB INVESTMENT MANAGEMENT INC 0.96% 1,403,948 +8.5% 0.01% $81,583,418
MAVERICK CAPITAL LTD 0.95% 1,377,738 +1.7% 0.93% $80,060,355
EVENTIDE ASSET MANAGEMENT, LLC 0.94% 1,374,292 +50% 1.3% $79,840,223
Pivotal bioVenture Partners Investment Advisor LLC 0.94% 1,372,425 0% 29% $79,751,617
UBS Group AG 0.92% 1,337,390 +22% 0.01% $77,715,733
GOLDMAN SACHS GROUP INC 0.87% 1,275,036 +18% 0.01% $74,092,342
FARALLON CAPITAL MANAGEMENT LLC 0.86% 1,261,000 +25120% 0.48% $73,276,710

Quarter history

Institutional holders across reporting periods

Holder count, reported shares/value, and median price by quarter.

Periods
24
Latest
Q1 2026
Rows shown
1-24 of 24
Period 13F Shares, Excl. Options Value, Excl. Options Value Change Price (Median) Investors
2026 Q1 162,525,689 $9,435,685,334 +$770,402,392 $58.11 335
2025 Q4 147,544,357 $6,807,567,397 +$262,484,596 $46.14 293
2025 Q3 141,285,706 $5,088,913,432 -$216,599,261 $36.02 282
2025 Q2 147,479,114 $4,794,596,759 -$48,097,035 $32.51 292
2025 Q1 133,025,604 $5,021,104,716 -$42,905,782 $37.76 302
2024 Q4 140,784,610 $11,525,526,197 +$183,138,339 $81.86 318
2024 Q3 136,507,040 $15,592,116,896 +$1,498,526,683 $114.27 325
2024 Q2 122,578,572 $9,264,040,265 +$268,135,107 $75.51 264
2024 Q1 119,065,967 $8,130,427,051 +$1,115,777,265 $68.31 249
2023 Q4 103,087,407 $6,473,142,685 +$69,029,370 $62.80 223
2023 Q3 101,381,209 $5,166,522,410 +$77,032,504 $50.98 202
2023 Q2 99,996,517 $4,993,540,992 +$865,860,362 $49.94 194
2023 Q1 84,121,058 $3,152,798,116 +$159,886,756 $37.48 186
2022 Q4 81,609,487 $3,913,093,743 +$1,140,362,544 $47.95 197
2022 Q3 56,496,728 $1,356,264,990 +$122,059,625 $24.00 121
2022 Q2 51,432,581 $1,119,137,255 +$31,274,087 $21.76 103
2022 Q1 49,852,918 $1,203,855,921 +$69,029,421 $24.15 86
2021 Q4 44,718,114 $1,063,493,543 +$32,023,661 $23.79 84
2021 Q3 43,198,231 $1,095,966,337 -$195,558 $25.37 77
2021 Q2 43,222,434 $972,744,067 -$14,050,462 $22.51 74
2021 Q1 44,022,105 $869,193,186 +$26,485,491 $19.75 73
2020 Q4 42,260,768 $1,118,933,017 +$58,331,379 $26.57 83
2020 Q3 37,761,937 $1,857,382,730 +$103,777,823 $49.38 60
2020 Q2 35,950,832 $1,126,753,000 +$1,126,753,000 $31.61 38
We use cookies and similar technologies to provide certain features, enhance the user experience and, if you allow them, measure engagement and deliver advertising. Analytics and marketing storage stay off until you grant consent. By clicking on "Agree and continue", you declare your consent to the use of the selected optional cookies. Manage preferences to update or revoke optional consent for future visits. For more information, see our Privacy Policy .